Waterloo Capital L.P. Boosts Position in STERIS plc $STE

Waterloo Capital L.P. boosted its holdings in shares of STERIS plc (NYSE:STE) by 20.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,298 shares of the medical equipment provider’s stock after acquiring an additional 392 shares during the period. Waterloo Capital L.P.’s holdings in STERIS were worth $552,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Allworth Financial LP lifted its stake in shares of STERIS by 7.3% during the second quarter. Allworth Financial LP now owns 661 shares of the medical equipment provider’s stock valued at $159,000 after buying an additional 45 shares during the period. Ashton Thomas Private Wealth LLC lifted its stake in shares of STERIS by 3.5% during the 1st quarter. Ashton Thomas Private Wealth LLC now owns 1,611 shares of the medical equipment provider’s stock worth $365,000 after purchasing an additional 54 shares during the period. Cetera Investment Advisers boosted its holdings in shares of STERIS by 0.9% during the first quarter. Cetera Investment Advisers now owns 6,999 shares of the medical equipment provider’s stock worth $1,586,000 after purchasing an additional 63 shares during the last quarter. Horizon Investments LLC grew its position in shares of STERIS by 4.7% in the first quarter. Horizon Investments LLC now owns 1,410 shares of the medical equipment provider’s stock valued at $320,000 after purchasing an additional 63 shares during the period. Finally, Alliance Wealth Advisors LLC UT grew its position in shares of STERIS by 2.0% in the first quarter. Alliance Wealth Advisors LLC UT now owns 3,305 shares of the medical equipment provider’s stock valued at $749,000 after purchasing an additional 64 shares during the period. 94.69% of the stock is currently owned by institutional investors and hedge funds.

STERIS Price Performance

Shares of NYSE:STE opened at $263.27 on Tuesday. The firm’s 50 day moving average is $247.21 and its two-hundred day moving average is $241.92. The firm has a market capitalization of $25.84 billion, a P/E ratio of 40.32 and a beta of 1.02. The company has a current ratio of 2.22, a quick ratio of 1.53 and a debt-to-equity ratio of 0.27. STERIS plc has a 52 week low of $200.98 and a 52 week high of $268.30.

STERIS (NYSE:STE) last posted its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.38 by $0.09. STERIS had a net margin of 11.61% and a return on equity of 14.17%. The business had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. During the same quarter in the prior year, the company posted $2.14 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. Analysts anticipate that STERIS plc will post 9.08 earnings per share for the current year.

STERIS Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 18th. Shareholders of record on Tuesday, November 18th will be paid a $0.63 dividend. The ex-dividend date is Tuesday, November 18th. This represents a $2.52 dividend on an annualized basis and a yield of 1.0%. STERIS’s payout ratio is 36.21%.

Wall Street Analysts Forecast Growth

STE has been the subject of a number of recent analyst reports. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a report on Tuesday, October 14th. Wall Street Zen raised shares of STERIS from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 14th. Finally, Morgan Stanley increased their target price on STERIS from $276.00 to $295.00 and gave the stock an “overweight” rating in a research report on Friday, August 8th. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $273.50.

Insider Buying and Selling at STERIS

In other news, CEO Daniel A. Carestio sold 159 shares of the firm’s stock in a transaction on Monday, October 6th. The shares were sold at an average price of $241.82, for a total transaction of $38,449.38. Following the transaction, the chief executive officer owned 51,096 shares in the company, valued at approximately $12,356,034.72. This trade represents a 0.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Renato Tamaro sold 5,036 shares of the business’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $257.55, for a total transaction of $1,297,021.80. Following the completion of the sale, the vice president owned 5,695 shares of the company’s stock, valued at $1,466,747.25. The trade was a 46.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 20,195 shares of company stock worth $5,312,571 over the last 90 days. 1.07% of the stock is currently owned by corporate insiders.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.